MLN 3126

Drug Profile

MLN 3126

Alternative Names: MLN3126

Latest Information Update: 23 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Takeda
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action CCR9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Sjogren's syndrome

Most Recent Events

  • 19 May 2015 Discontinued - Phase-I for Sjogren's syndrome in USA (PO)
  • 17 May 2015 Takeda terminates a phase I trial in Healthy volunteers in USA (NCT02447458)
  • 01 Sep 2013 Takeda initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT02447458)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top